MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with P

Pentoxifylline

Pentoxifylline 400mg modified-release tablets

Use with caution

Stability notes for Pentoxifylline 400mg modified-release tablets

Protect from light and store in well-closed, light-resistant containers.

Provenance

Compatibility recommendation derived from Trental 400 modified-release tablets (Sanofi).

Suppliers (4) of Pentoxifylline 400mg modified-release tablets
Pentoxifylline 400mg modified-release tablets (Neuraxpharm UK Ltd)
Trental 400 modified-release tablets (Lexon (UK) Ltd)
Trental 400 modified-release tablets (Pilsco Ltd)
Trental 400 modified-release tablets (Sigma Pharmaceuticals Plc)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.